Loading people...
Jeffrey Finer is a Venture Partner at Third Rock Ventures, a leading life sciences venture capital firm. He is a distinguished scientist and entrepreneur known for his expertise in drug discovery and his pivotal role in creating new biotechnology companies.
Jeffrey Finer focuses on investments within the life sciences sector, particularly in novel drug discovery platforms, therapeutic development, and the creation of new biotechnology companies. His interests span areas like oncology, immunology, and neuroscience.
Jeffrey Finer works as a Venture Partner at Third Rock Ventures, a prominent venture capital firm dedicated to building and investing in groundbreaking life sciences companies.
Jeffrey Finer is the President and Chief Executive Officer of Septerna and a Venture Partner at Third Rock Ventures in the San Francisco Bay Area. He holds an MD and a PhD in Biochemistry from the Stanford University School of Medicine, alongside a BS in Chemistry and Biology from MIT. Prior to his current executive positions, he accumulated over thirty years of research and clinical experience, holding senior leadership roles including Vice President of Research Technology at Theravance Biopharma and Director of Drug Discovery Technologies at Cytokinetics. As a venture capitalist and serial entrepreneur, he has helped launch multiple early-stage biotechnology firms, including Celsius Therapeutics, which AbbVie acquired for $250 million in June 2024. His current focus centers on advancing life sciences portfolio companies and developing novel drug discovery platforms to create first-in-class drugs.
Jeffrey Finer is a distinguished Venture Partner at Third Rock Ventures, a leading investor and company builder in the life sciences sector. His role is pivotal in identifying unmet medical needs and translating cutting-edge scientific discoveries into viable therapeutic companies. At Third Rock Ventures, Finer is deeply involved in the firm's unique approach to company creation, often working from the ground up to establish new biotechnology ventures that aim to deliver transformative medicines to patients.
Finer's investment focus areas are broad within life sciences, with a particular emphasis on novel drug discovery platforms and therapeutic development. He seeks opportunities that leverage innovative science to address significant diseases, including oncology, immunology, and neuroscience. His work involves rigorous scientific evaluation, strategic planning, and hands-on guidance to nurture early-stage concepts into successful biotech enterprises. This commitment to foundational science and strategic execution underpins Third Rock Ventures' reputation for building impactful companies.
Before joining Third Rock Ventures, Jeffrey Finer built a remarkable career marked by significant scientific contributions and entrepreneurial success. He earned his Ph.D. in Biophysics from Stanford University, laying a strong foundation for his subsequent work in drug discovery. Finer's career includes leadership roles at various biotech companies, where he was instrumental in advancing research and development programs. Notably, he was a co-founder of Revolution Medicines, a Third Rock Ventures-founded company focused on developing targeted therapies for cancer. His experience spans both academic research and industry, providing him with a comprehensive perspective on the challenges and opportunities in biotechnology.
Through his work at Third Rock Ventures, Jeffrey Finer continues to shape the future of medicine. He plays a crucial role in assembling scientific teams, developing strategic roadmaps, and securing the necessary resources for new companies to thrive. His deep scientific acumen combined with his entrepreneurial spirit makes him a key figure in the life sciences investment landscape, driving the creation of companies that promise to deliver significant patient benefit. His involvement ensures that Third Rock Ventures remains at the forefront of biotech innovation, fostering the next generation of therapeutic breakthroughs.
